Evidence Table 152. KQ3—Dichotomous—Prothrombin time (above/below threshold)

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lee200836Parallel | N/A | At high risk for CHD | Warfarin (3.5) | Ginseng | 12 |  | No Treatment | 13 | 0 |  | No events occurred. No data reported. | Medium |
| Napoli199852Parallel | N/A | Unclear | Pravastatin (20-40) | Vitamin E |  |  | No Treatment |  |  |  | No differences in routine laboratory tests or adverse events were registered during the study (data not shown); in particular there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups.” | Medium |